stockrow
Saturday 7 November 2026
Export TVGN’s income statement to Excel — free account
Tevogen Inc.
TVGN Healthcare Biotechnology
- EPS
- +11.1%
- Free cash flow
- +5.78%
- Total debt
- +45.5%
Quarter to June 2026, against a year earlier
5.35
0.21
−3.78%
Follow TVGN
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '17 | |
|---|---|---|---|---|---|---|
Current Ratio |
0.22 | 0.26 | 0.02 | 0.78 | 13.32 | — |
Net Debt/EBITDA |
(0.15) | 0.01 | (1.56) | 0.14 | 1.90 | — |
Debt/Assets |
100.39% | 28.89% | 258.29% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.53) | (0.15) | (0.15) | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.46 | 1.17 | 0.14 | (0.05) | 24.87 | — |
Capex/Depreciation |
(0.13) | 0.00 | (0.35) | — | — | — |
Interest Coverage |
(133.64) | (291.11) | (7.33) | (0.19) | (11.48) | — |
| 165.04% | 18.70% | 110.75% | (30.39%) | 0.00% | — | |
| (683.91%) | (229.14%) | (33.35%) | 1.24% | (0.02%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
500.62% | 160.89% | 72.60% | (5,792.90%) | (3.92%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | — | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | — | — |
Free Cash Flow per Share |
(3.73) | (4.09) | (16.78) | (0.80) | (2.98) | — |
Cash per Share |
0.17 | 0.44 | 2.13 | 0.48 | 1.44 | — |
Shareholders Equity per Share |
(2.48) | (2.28) | (190.77) | (55.02) | (59.36) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(2.48) | (2.28) | (190.77) | (55.02) | (59.36) | — |
Free Cash Flow |
(12.39) | (12.00) | (8.30) | (0.22) | (0.71) | — |
Working Capital |
(5.53) | (6.68) | (83.76) | (0.08) | 0.73 | — |
Capital Expenditures |
(0.06) | — | (0.13) | — | — | — |
Net Current Asset Value |
(11.08) | (7.77) | (98.21) | (371.65) | (366.29) | — |
| Other line items | ||||||
Quick Ratio |
0.10 | 0.16 | 0.02 | 0.37 | 5.80 | — |
Depreciation/Fixed assets |
2.99 | 1.36 | 0.82 | — | — | — |
Cash ROIC |
377.57% | 273.26% | 10.49% | 1.47% | 5.14% | — |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(3.71) | (4.09) | (16.51) | (0.80) | (2.98) | — |
Capex per Share |
(0.02) | 0.00 | (0.27) | 0.00 | 0.00 | — |
Average Receivables |
0.16 | 0.25 | — | — | — | — |
Average Payables |
4.27 | 4.31 | 1.81 | 0.12 | — | — |
Average Assets |
3.92 | 4.48 | 181.32 | 355.00 | 176.43 | — |
Average Common Equity |
(16.25) | (54.95) | (54.61) | (14.51) | — | — |
Capex to Sales |
0.00 | — | 0.00 | — | — | — |
Columns are period end dates · fundamentals updated 26 Oct 2026